Calliditas Year-end report, January - December 2023
STOCKHOLM, Feb. 21, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
2023: Full approval for TARPEYO in the US; a year of successes
OCTOBER – DECEMBER 2023
|
JANUARY – DECEMBER 2023
|
"In December we were granted full approval by the FDA for TARPEYO - a crowning achievement after many years of striving to bring an approved disease modifying treatment to patients with primary IgAN."
Lesen Sie auch
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte